Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,745
  • Shares Outstanding, K 14,837
  • Annual Sales, $ 710 K
  • Annual Income, $ -21,410 K
  • EBIT $ -18 M
  • EBITDA $ -17 M
  • 60-Month Beta 0.36
  • Price/Sales 38.71
  • Price/Cash Flow N/A
  • Price/Book 1.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.33
  • Low Estimate -0.42
  • Prior Year -2.50
  • Growth Rate Est. (year over year) +84.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7350 +8.93%
on 11/19/24
2.4843 -23.92%
on 10/28/24
-0.1600 (-7.80%)
since 10/22/24
3-Month
1.7350 +8.93%
on 11/19/24
2.6700 -29.21%
on 08/23/24
-0.7400 (-28.14%)
since 08/22/24
52-Week
0.7707 +145.23%
on 06/11/24
23.9000 -92.09%
on 12/07/23
-17.1100 (-90.05%)
since 11/22/23

Most Recent Stories

More News
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

LGVN : 1.8900 (+1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

LGVN : 1.8900 (+1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

LGVN : 1.8900 (+1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

LGVN : 1.8900 (+1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

LGVN : 1.8900 (+1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

LGVN : 1.8900 (+1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

LGVN : 1.8900 (+1.07%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

LGVN : 1.8900 (+1.07%)
LGVNR : 0.0005 (-37.50%)
Annovis Bio (NYSE: ANVS) Presented Recent Achievements at H.C. Wainwright Conference

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

LGVN : 1.8900 (+1.07%)
ANVS : 6.65 (-2.06%)
AVXL : 9.11 (+1.00%)
Stocks Set to Open Higher as Investors Await U.S. Jobs Data and Big Tech Earnings, Fed Meeting on Tap

September S&P 500 E-Mini futures (ESU24) are up +0.29%, and September Nasdaq 100 E-Mini futures (NQU24) are up +0.38% this morning as market participants looked ahead to earnings reports from major tech...

ESU24 : 5,699.99s (-0.31%)
NQU24 : 19,808.01s (-0.21%)
MMM : 128.42 (+0.86%)
CHTR : 388.27 (+1.15%)
DECK : 192.15 (+5.63%)
DXCM : 72.83 (-2.19%)
MSFT : 417.00 (+1.00%)
AMZN : 197.12 (-0.64%)
META : 559.14 (-0.70%)
AAPL : 229.87 (+0.59%)
SBUX : 102.50 (+2.44%)
MCD : 290.28 (+0.63%)

Business Summary

Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

See More

Key Turning Points

3rd Resistance Point 2.0225
2nd Resistance Point 1.9687
1st Resistance Point 1.9294
Last Price 1.8900
1st Support Level 1.8363
2nd Support Level 1.7825
3rd Support Level 1.7432

See More

52-Week High 23.9000
Fibonacci 61.8% 15.0646
Fibonacci 50% 12.3354
Fibonacci 38.2% 9.6061
Last Price 1.8900
52-Week Low 0.7707

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar